Verified
Eurofins Genomics Germany GmbH
Reach for the stars – We are glad to assist you
About Eurofins
FAST. We produce and analyze DNA & RNA
Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, USA and Asia, is an internationally leading provider of DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets.
COMPLETE. We support from research to application
We pool our experience and expertise in the fields of genomics, agrosciences, pharmaceutical and environmental research as well as food and feed tests in an international network of exceptional experts, who can rely on state-of-the-art instruments, methods and technologies. This unique constellation allows us to provide you with the best possible solution and flexibility for any project at any time, – from standard projects to challenging research projects and complex strategies for large Interdisciplinary companies.
RELIABLE. Pharma, food, diagnostics, agriculture & biotechnology trust us
Highly automated and lean-optimized lab processes deliver highly reliable results. This is documented by ISO 17025 accreditation, as well as ISO 13485, GLP, GCP and cGMP certification.
- Founding: 1990
- Focus : Manufacturer
- Employees: 51-200
- Industry : Laboratory analysis / Laboratory measurement technology
Product portfolio of Eurofins
News about Eurofins
Here you will find Eurofins Genomics Germany GmbH
See the theme worlds for related content
Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!
Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!
Topic world Digitalization in the laboratory
The topic world Digitalization in the lab presents innovations and trends from digital data systems (ELN, LIMS) to laboratory robots and networked devices (IoT) to AI and machine learning.
Topic world Digitalization in the laboratory
The topic world Digitalization in the lab presents innovations and trends from digital data systems (ELN, LIMS) to laboratory robots and networked devices (IoT) to AI and machine learning.
Last viewed contents
YMC Europe GmbH - Dinslaken, Germany
Bio-Rad Laboratories Ltd. - Watford, United Kingdom
FRYKA-Kältetechnik GmbH - Esslingen am Neckar, Germany
BASF increases prices for Vitamin E and A feed grade
Cell Medica granted Orphan Drug designation for novel cellular therapy
Drug costs vary by more than 600% in study of 10 high-income countries
Are the high prices of cancer drugs justified? - Does the cost correspond to the particular drug’s effectiveness in combating the disease?
NextPharma inaugurates new production facility for liquid pharmaceuticals in Limay, France - "This project reflects our commitment to bringing the production of essential medicines back to France..."
Spanish startup receives investment for novel disinfection method against “killer fungus” - The UJI spin-off Molecular Sustainable Solutions receives an investment from BeAble Capital to boost its disinfection and sterilization methods
Merck Opens Climate-Neutral €150 Million Manufacturing Facility in Ireland - The Blarney Business Park facility is part of Merck’s largest Life Science investment to date
Simtra BioPharma Solutions expands U.S. manufacturing capacity for injectable medicines - Simtra positioned to become the first CDMO to offer commercial-scale drug product manufacturing of antibody-drug conjugates in the United States
